New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?

Vesa M. Olkkonen; Juha Sinisalo; Matti Jauhiainen

doi:10.1016/j.atherosclerosis.2018.03.019

New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?

Vesa M. Olkkonen, Juha Sinisalo, Matti Jauhiainen

Forskningsoutput: Tidskriftsbidrag › Översiktsartikel › Peer review

Originalspråk	engelska
Tidskrift	Atherosclerosis
Volym	272
Sidor (från-till)	27-32
Antal sidor	6
ISSN	0021-9150
DOI	https://doi.org/10.1016/j.atherosclerosis.2018.03.019
Status	Publicerad - maj 2018
MoE-publikationstyp	A2 Granska artikel i en vetenskaplig tidskrift

Vetenskapsgrenar

3111 Biomedicinska vetenskaper
3121 Allmänmedicin, inre medicin och annan klinisk medicin

Åtkomst av dokument

10.1016/j.atherosclerosis.2018.03.019

New medications targeting Slutlig publicerad version, 606 KB

Citera det här

@article{bbc228acbd904baf94456175e2dcae5b,

title = "New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?",

keywords = "3111 Biomedicine, 3121 General medicine, internal medicine and other clinical medicine, ANGPTL3, Antibody therapy, apoC-III, ASO, CVD, TRL, CORONARY EVENTS, ANGIOPOIETIN-LIKE PROTEINS, OF-FUNCTION MUTATIONS, LOW-DENSITY LIPOPROTEINS, METABOLISM, ENDOTHELIAL-CELLS, B GENE, APOLIPOPROTEIN-C-III, FAMILIAL COMBINED HYPOLIPIDEMIA, PLASMA TRIGLYCERIDES",

author = "Olkkonen, {Vesa M.} and Juha Sinisalo and Matti Jauhiainen",

year = "2018",

month = may,

doi = "10.1016/j.atherosclerosis.2018.03.019",

language = "English",

volume = "272",

pages = "27--32",

journal = "Atherosclerosis",